Quercetin inhibition of porcine intestinal alpha coronavirus in vitro and in vivo.

Publication date: Apr 03, 2024

Porcine acute diarrhea syndrome coronavirus (SADS-CoV) is one of the novel pathogens responsible for piglet diarrhea, contributing to substantial economic losses in the farming sector. The broad host range of SADS-CoV raises concerns regarding its potential for cross-species transmission. Currently, there are no effective means of preventing or treating SADS-CoV infection, underscoring the urgent need for identifying efficient antiviral drugs. This study focuses on evaluating quercetin as an antiviral agent against SADS-CoV. In vitro experiments showed that quercetin inhibited SADS-CoV proliferation in a concentration-dependent manner, targeting the adsorption and replication stages of the viral life cycle. Furthermore, quercetin disrupts the regulation of the P53 gene by the virus and inhibits host cell cycle progression induced by SADS-CoV infection. In vivo experiments revealed that quercetin effectively alleviated the clinical symptoms and intestinal pathological damage caused by SADS-CoV-infected piglets, leading to reduced expression levels of inflammatory factors such as TLR3, IL-6, IL-8, and TNF-α. Therefore, this study provides compelling evidence that quercetin has great potential and promising applications for anti- SADS-CoV action.

Open Access PDF

Concepts Keywords
Antiviral Antiviral activity
Coronavirus Cell cycle
Efficient P53
P53 Quercetin
Piglets SADS-CoV

Semantics

Type Source Name
drug DRUGBANK Quercetin
disease MESH syndrome
disease IDO host
disease VO effective
disease MESH infection
disease VO efficient
disease IDO replication
pathway KEGG Viral life cycle
disease VO gene
disease VO NS3
drug DRUGBANK Amino acids
disease IDO zoonosis
disease VO vaccine
drug DRUGBANK Aloe Vera Leaf
disease VO Rho
drug DRUGBANK Methylene blue
drug DRUGBANK Gemcitabine
drug DRUGBANK Mycophenolate mofetil
disease MESH viral infections
pathway KEGG Apoptosis
disease VO Viruses
drug DRUGBANK Streptomycin
drug DRUGBANK Amphotericin B
drug DRUGBANK Trypsin
disease MESH Infectious Diseases
disease IDO assay
disease VO viability
disease VO manufacturer
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Desipramine
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Microcrystalline cellulose
drug DRUGBANK Methylergometrine
disease VO USA
drug DRUGBANK Esomeprazole
disease VO time
disease IDO infectivity
drug DRUGBANK Ethanol
drug DRUGBANK Phenobarbital
disease VO vein
drug DRUGBANK Coenzyme M
disease MESH death
disease VO dose
disease VO titer
disease VO inactivation
drug DRUGBANK Ademetionine
drug DRUGBANK Trestolone
drug DRUGBANK Proline
drug DRUGBANK Tretamine
disease MESH weight loss
disease IDO symptom
pathway KEGG Viral replication
disease MESH Inflammation
disease VO organ
drug DRUGBANK Tretinoin
drug DRUGBANK Ginseng
disease IDO production
drug DRUGBANK Hypericin
drug DRUGBANK Allicin
drug DRUGBANK Indoleacetic acid
disease MESH oxidative stress
disease VO Gap
disease IDO process
disease MESH swine fever
drug DRUGBANK Nitazoxanide
disease MESH dehydration
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Emodin
drug DRUGBANK Guanosine
disease MESH repression
disease MESH influenza
disease MESH cancer
disease IDO quality
disease VO African swine fever virus
disease VO mouth
disease MESH Hepatitis
disease VO Hsp70
disease IDO cell
drug DRUGBANK L-Aspartic Acid
disease VO Classical swine fever virus
disease MESH circovirus infection
pathway KEGG Cell cycle

Original Article

(Visited 1 times, 1 visits today)